肝内胆管癌术后辅助治疗研究进展

Research advances of postoperative adjuvant therapy for intrahepatic cholangiocarcinoma

手术治疗是肝内胆管癌(intrahepatic cholangiocarcinoma, ICC)最重要的根治性手段,但其术后复发率高,预后差,辅助治疗有助于进一步提升ICC病人远期生存,是目前ICC领域研究的热点。近年来,随着免疫治疗、靶向治疗、化疗方案及局部治疗的不断进步,国内外学者在ICC辅助治疗领域进行了积极探索,取得了丰富成果。此文对目前ICC辅助治疗研究结果和正在进行的临床研究进行综述,总结了化疗、放疗、经导管动脉化疗栓塞术(transcatheter arterial chemoembolization, TACE)、靶向治疗、免疫治疗等手段在ICC辅助治疗中的作用。

Surgery has been the most important radical option for intrahepatic cholangiocarcinoma(ICC).However,its postoperative recurrence rate remains high and the prognosis is poor.Adjuvant therapy is helpful to further improve the long-term survival of ICC patients.It is a research hotspot in the field of ICC.In recent years,with continuous developments of immunotherapy,targeted therapy,chemotherapy and local therapy,researchers have paid greater attention to the research of adjuvant therapy for ICC.This review summarized the latest research results and ongoing clinical trials of adjuvant therapy for ICC and discussed the roles of chemotherapy,radiotherapy,transcatheter arterial chemoembolization(TACE),targeted therapy and immunotherapy for ICC.